Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Mdfirst Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,240,706

165 payments

Through program year 2025, Mdfirst Research LLC is reported as receiving $1,240,706 in research payments, across 165 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $381,129 25
2024 Research $417,337 25
2023 Research $162,302 34
2022 Research $126,099 30
2021 Research $62,763 23
2020 Research $91,076 28

Breakdown

Who paid Research payments · program years 2020–2025
  1. Eli Lilly and Company $419,781 9 payments
  2. GlaxoSmithKline, LLC. $403,351 123 payments
  3. DiaSorin Molecular LLC $285,000 1 payment
  4. Sanofi US Services Inc. $84,308 26 payments
  5. Chiesi USA, Inc. $48,202 5 payments
  6. Eli Lilly Export S.A. Puerto Rico Branch $65 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Study of Orforglipron (Ly3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (Achieve-1) $314,175 4 payments
  2. A Multi-Site Clinical Evaluation of the LIAISON NES Group A Strep (GAS) Assay in Symptomatic Patients (DSM-PROT-005254) $285,000 1 payment
  3. A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, DO $242,093 82 payments
  4. A Multicenter Randomized, Double-Blind, Placebo-Controlled Phase 2 Stu $144,078 34 payments
  5. A Study of Orforglipron (Ly3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (Achieve-1) $91,186 1 payment
  6. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $84,308 26 payments
  7. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $32,202 2 payments
  8. A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $17,180 7 payments
  9. A 52-Week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500) Study to Evaluate the Efficacy and Safety of Two Doses of Chf6001 Dpi (Tanimilast) As Add-On to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (Pillar) (Pi $16,000 3 payments
  10. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $13,130 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record